RxDoctor Payments Data

Michael Sonnier, APRN

Family · Lafayette, LANPI 1336237205

Payments from drug & device makers

$522in general payments, 2019–2025

Across 23 payments — averaging $22.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$193
  • Revance Therapeutics, Inc.$88
  • Collegium Pharmaceutical, Inc.$58
  • Exact Sciences$34
  • GSK$34
  • Ardelyx, Inc.$31
  • plus $84 from 3 others

What the payments were for

  • Food & beverage$522100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$522 in reported general payments places this provider in the 50th percentile of 3,610 family providers in Louisiana.

See all family providers in Louisiana

Medicare billing

Part B allowed, 2024
$1,722
Medicare patients
15
Services billed
18

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide137$129,566
MounjaroTirzepatide60$69,168
Trelegy ElliptaFluticasone/Umeclidin/Vilanter91$60,292
JardianceEmpagliflozin72$49,721
FarxigaDapagliflozin Propanediol46$27,770
LinzessLinaclotide32$20,139
EliquisApixaban30$16,222
SymbicortBudesonide/Formoterol Fumarate51$11,714
JanumetSitagliptin Phos/Metformin Hcl18$10,189
TradjentaLinagliptin19$10,041
XareltoRivaroxaban15$8,455
Lantus SolostarInsulin Glargine,hum.Rec.Anlog63$7,957
KerendiaFinerenone12$7,780
JanuviaSitagliptin Phosphate16$7,588
LyricaPregabalin11$6,692

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$31$129,566137 claims
GSKTrelegy Ellipta, Shingrix$34$62,581102 claims
AstraZenecaFarxiga, Symbicort$30$39,48397 claims
AbbVieLinzess$193$20,13932 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 3,610 family providers in Louisiana.

Other family in Lafayette

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →